Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$50.22 -2.01 (-3.85%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$50.22 0.00 (-0.01%)
As of 02/14/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TARS vs. ROIV, ASND, RVMD, BPMC, LEGN, AXSM, LNTH, TLX, BBIO, and NUVL

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), BridgeBio Pharma (BBIO), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs.

Roivant Sciences (NASDAQ:ROIV) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.

Roivant Sciences currently has a consensus target price of $18.08, suggesting a potential upside of 71.24%. Tarsus Pharmaceuticals has a consensus target price of $56.00, suggesting a potential upside of 11.51%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

Roivant Sciences has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$124.79M61.60$4.35B$5.651.87
Tarsus Pharmaceuticals$17.45M110.02-$135.89M-$3.81-13.18

Roivant Sciences has a net margin of 3,827.42% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Roivant Sciences' return on equity of -14.65% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences3,827.42% -14.65% -13.19%
Tarsus Pharmaceuticals -103.64%-55.86%-39.28%

Roivant Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

In the previous week, Roivant Sciences had 7 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 11 mentions for Roivant Sciences and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.60 beat Roivant Sciences' score of 0.40 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tarsus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Roivant Sciences received 5 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 77.94% of users gave Roivant Sciences an outperform vote while only 66.67% of users gave Tarsus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Roivant SciencesOutperform Votes
53
77.94%
Underperform Votes
15
22.06%
Tarsus PharmaceuticalsOutperform Votes
48
66.67%
Underperform Votes
24
33.33%

Summary

Roivant Sciences beats Tarsus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.92B$3.09B$5.76B$9.21B
Dividend YieldN/A1.67%5.27%3.99%
P/E Ratio-13.1845.4825.5919.43
Price / Sales110.02297.96469.2576.00
Price / CashN/A192.7646.0638.90
Price / Book8.444.057.305.05
Net Income-$135.89M-$40.60M$3.19B$222.81M
7 Day Performance-2.98%3.50%1.69%1.29%
1 Month Performance7.95%4.18%4.12%1.52%
1 Year Performance63.58%-10.55%22.23%16.53%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
1.3503 of 5 stars
$50.22
-3.8%
$56.00
+11.5%
+63.6%$1.92B$17.45M-13.1850
ROIV
Roivant Sciences
3.6146 of 5 stars
$10.77
-1.1%
$17.93
+66.5%
-8.9%$7.84B$124.79M1.91860Earnings Report
Insider Trade
Gap Up
ASND
Ascendis Pharma A/S
2.4556 of 5 stars
$119.47
-1.2%
$191.57
+60.3%
-7.9%$7.25B$288.08M-14.79640Earnings Report
Analyst Revision
RVMD
Revolution Medicines
4.6095 of 5 stars
$42.02
-0.4%
$66.25
+57.7%
+37.8%$7.07B$11.58M-11.70250Positive News
BPMC
Blueprint Medicines
3.115 of 5 stars
$103.88
-1.0%
$123.72
+19.1%
+4.1%$6.60B$434.42M-49.23640Earnings Report
Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
LEGN
Legend Biotech
2.7714 of 5 stars
$35.78
+1.1%
$79.50
+122.2%
-37.3%$6.53B$285.14M-37.661,800Positive News
Gap Up
AXSM
Axsome Therapeutics
4.6482 of 5 stars
$126.94
+20.0%
$134.00
+5.6%
+41.3%$6.15B$270.60M-19.44380Insider Trade
High Trading Volume
LNTH
Lantheus
4.5808 of 5 stars
$86.90
-2.0%
$131.86
+51.7%
+39.1%$6.04B$1.50B14.46700Positive News
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$18.05
0.0%
$22.00
+21.9%
N/A$6.04BN/A0.00N/APositive News
Gap Up
BBIO
BridgeBio Pharma
4.5511 of 5 stars
$31.76
-0.3%
$49.00
+54.3%
-6.2%$6.00B$9.30M-13.18400Short Interest ↓
NUVL
Nuvalent
2.6237 of 5 stars
$83.40
-2.7%
$112.36
+34.7%
-9.6%$5.93BN/A-24.0340Positive News

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners